Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29853520 | 1.00 | HPGD (0.52) | HPGDALDH1A1KDM4EHSD17B10AKR1C3 | |
| SCHEMBL30046118 | 0.88 | ALDH1A1 (0.54) | HPGDALDH1A1KDM4EHSD17B10AKR1C3 | |
| SCHEMBL2436724 | 0.88 | ALDH1A1 (0.54) | HPGDALDH1A1KDM4EHSD17B10AKR1C3 | |
| SCHEMBL16930305 | 0.86 | HTT (0.44) | HPGDALDH1A1KDM4ENPC1MAPT | |
| SCHEMBL2742615 | 0.85 | HSD17B10 (0.68) | HPGDKDM4EHSD17B10AKR1C3MAPT | |
| SCHEMBL26810800 | 0.84 | ALDH1A1 (0.39) | HPGDALDH1A1KDM4EHSD17B10AKR1C3 | |
| SCHEMBL16294203 | 0.84 | POLB (0.48) | HPGDALDH1A1KDM4EHSD17B10HDAC1 | |
| Bromide SCHEMBL29853696 | 0.83 | HSD17B10 (0.66) | HPGDKDM4EHSD17B10AKR1C3MAPT | |
| SCHEMBL10624636 | 0.83 | HSD17B10 (0.49) | HPGDHSD17B10AKR1C3HDAC1NPC1 | |
| SCHEMBL1097014 | 0.83 | HSD17B10 (0.49) | HPGDALDH1A1KDM4EHSD17B10AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712958-A2 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Vandria SA (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-20260070920-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-12 | — | — | US | disclosed |
| EP-4169925-B1 | PROCESS TO MAKE N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-11-18 | — | — | US | disclosed |
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-07-15 | — | — | US | disclosed |
| US-12351567-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-07-08 | — | — | US | disclosed |
| US-12331060-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-06-17 | — | — | US | disclosed |
| US-20240424006-A1 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | VANDRIA SA (CH) | 2024-12-26 | — | — | US | disclosed |
| WO-2024255412-A1 | SPIRO HETEROCYCLIC COMPOUND AND USE THEREOF | 广州必贝特医药股份有限公司 | 2024-12-19 | — | — | WO | disclosed |
| WO-2024236367-A2 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | VANDRIA SA (CH) | 2024-11-21 | — | — | WO | disclosed |
| EP-3345903-A1 | TETRACYCLIC COMPOUNDS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2018-07-11 | — | — | EP | disclosed |
| EP-2975024-B1 | TETRACYCLIC COMPOUNDS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-03-28 | — | — | EP | disclosed |
| US-20160340308-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9440922-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-09-13 | — | — | US | disclosed |
| EP-2441753-B1 | TETRACYCLIC COMPOUND | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-03-30 | — | — | EP | disclosed |
| EP-2975024-A1 | TETRACYCLIC COMPOUNDS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-9126931-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2441753-A1 | TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424006-A1 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UBQLN2, SOD1, UBQLN1 | HPGD 2759/4885ALDH1A1 1601/4885KDM4E 4157/4885 |
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | HPGD 499/4885ALDH1A1 851/4885KDM4E 4333/4885 |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | HPGD 4633/4885ALDH1A1 1165/4885KDM4E 903/4885 |
| US-12331060-B2 | N-substituted tetrahydrothienopyridine derivatives and uses thereof | TPMT, NNMT, NLN | HPGD 1055/4885ALDH1A1 1472/4885KDM4E 3338/4885 |
| US-12351567-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | HPGD 499/4885ALDH1A1 851/4885KDM4E 4333/4885 |
| US-20160340308-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | HPGD 4633/4885ALDH1A1 1165/4885KDM4E 903/4885 |
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | HPGD 499/4885ALDH1A1 851/4885KDM4E 4333/4885 |
| US-20260070920-A1 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | CCR3, SCN1B, NR3C1 | HPGD 3292/4885ALDH1A1 1462/4885KDM4E 3018/4885 |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | HPGD 4633/4885ALDH1A1 1165/4885KDM4E 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.